Phase 3 N=32 Early Treatment of Cytokine Storm Syndrome in Covid-19
Cytokine Storm · COVID-19
Primary: Subjects Discharged From the Hospital Alive and Without the Need for Mechanical Ventilation. — 10; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=5 Treat COVID-19 Patients With Regadenoson
COVID-19 · Lung Inflammation
Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free
Phase 4 N=16 Fluoxetine to Reduce Intubation and Death After COVID19 Infection
COVID-19 · Cytokine Storm
Primary: Number of Outpatient Subject Hospitalizations — 0; 0 Participants
Phase 2 N=25 Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
Covid19 · Pneumonia, Viral
Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…
Phase 2 N=83 Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
COVID-19 Pneumonia · Acute Lung Injury · ARDS
Primary: Number of Subjects Alive and Free of Respiratory Failure — 26; 20 Participants — p=0.0440
Phase 2 N=32 Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis
COVID-19
Primary: Number of Participants With Clinical Response in Maximum Temperature (Tmax) — 8; 16 Participants
Phase 3 N=342 Treatment of COVID-19 Patients With Anti-interleukin Drugs
COVID-19
Primary: Time to Clinical Improvement — 12; 12; 11; 12 days
Phase 2 N=28 Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
Sars-CoV2 · Acute Respiratory Distress Syndrome · COVID-19
Primary: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs) — 0; 0 proportion of participant
Phase 2 N=20 Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation
COVID-19 · Hypoxia
Primary: Number of Participants With Adverse Events Related to High Dose Intravenous Vitamin C (HDIVC) — 0; 0 Participants
Phase 2 N=228 CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)
Corona Virus Infection
Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 19; 28…
Phase 2 N=45 Canakinumab in Covid-19 Cardiac Injury (The Three C Study)
COVID-19 · SARS-CoV 2
Primary: Number of Participants With Clinical Improvement at Day 14 — 9; 7; 9 Participants
Phase 3 N=432 Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
Cytokine Storm (Covid-19)
Primary: Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care — 34; 17 Participants — p=0.769
Phase 3 N=1,971 Immune Modulators for Treating COVID-19
Covid19
Primary: Number of Participants Who Had Recovered by Day 28 — 421; 405; 414; 397 Participants — p=0.0793
Phase 2 N=17 A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).
COVID-19
Primary: Time to Improvement in Oxygenation — 4 Days
Phase 2 N=178 A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
COVID-19
Primary: Ventilator Free Survival — 58; 19; 44 Participants
Phase 2 N=20 A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)
Covid19
Primary: Respiratory Failure-free Survival in Participants With Moderate-severe COVID-19 Who Are Treated With ATI-450 — 50; 60 percentage of total patients
Phase 3 N=46 Cytokine Removal in Cardiopulmonary Bypass Patients
Elective Cardiac Surgical Interventions
Primary: IL-6 — 0; 0; 0; 0 pg/ml
Phase 3 N=243 Efficacy of Tocilizumab on Patients With COVID-19
SARS-CoV 2
Primary: Mechanical Ventilation or Death — 9.9; 10.0; 10.6; 12.5 percentage of patients with event — p=0.64
Phase 3 N=30 Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection
COVID-19
Primary: Evaluate the Ability of Inhaled Nasal Sodium Pyruvate to Change COVID-19 Viral Titers. — 5.61; 6.57; 4.67; 5.86 Log10 viral RNA copies — p=0.0197
Phase 2 N=28 Duvelisib to Combat COVID-19
COVID-19
Primary: Overall Survival as Measured by Number of Participants Alive Through 28 Days — 10; 8 Participants
Phase 3 N=1,032 Novel Experimental COVID-19 Therapies Affecting Host Response
COVID-19 · SARS-CoV-2 Infection · Coronavirus Infection
Primary: Oxygen Free Days Through Day 28. — 9.0; 11.3; 8.1; 10.5 Days
Phase 4 N=20 Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity
COVID-19
Primary: Plasma Viscosity — 2.35; 2.47; 1.61; 2.47 cP
Phase 2 N=81 Cardiovascular Effects of COVID-19
COVID-19
Primary: Hospital Length of Stay (LOS) — 5; 10; 25 days
Phase 3 N=73 MIS-C Comparative Effectiveness Study
Multisystem Inflammatory Syndrome-Children
Primary: Number of Participants Needing Additional Anti-inflammatory Therapy Within the First Week of First Randomization — 10; 10; 14 Participants
N/A N=21 Inflammatory Cytokine Quantification in Infants
Sepsis · Congenital Diaphragmatic Hernia · Neonatal Cardiopulmonary Failure
Primary: TNF-alpha, Baseline — 8.88 pg/mL
Phase 4 N=34 Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19
Sars-CoV2
Primary: Mechanical Ventilation — 2; 7 Participants
Phase 2 N=36 Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
Severe Acute Respiratory Syndrome · Respiratory Failure · Acute Respiratory Distress Syndrome
Primary: PaO2/FiO2 Change (Increase) From Pre-to-post Intervention — 16.9; 29.8 percent change
Phase 3 N=149 Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Coronavirus Disease 2019 COVID-19
Primary: Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline — 56; 5; 27 Participants — p=.28
Phase 2 N=212 A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19
Critical Confirmed Coronavirus Disease (COVID)-19
Primary: Time to Sustained Improvement of at Least 2 Categories on 6-point Ordinal Clinical Recovery Scale (CRS): Primary Analysis Set — 17.00; 23.00 Days
Phase 2 N=20 Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
Cytokine Release Syndrome · COVID19
Primary: C-reactive Protein (CRP) Levels at Baseline and Day 14 — 75.45; 59.8; 41.9; 38.7 mg/L